Lakeway, NY — (US MARKET BUZZ) — 12/17/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on EXACT Sciences Corporation (NASDAQ:EXAS), Gilead Sciences Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG).
EXACT Sciences Corporation (NASDAQ:EXAS)’s shares declined 5.72% to $25.51. The company on Dec. 16 announced the pricing of the public offering of 4,000,000 common shares previously sold to Jefferies LLC and Robert W. Baird & Co. Incorporated, as underwriters of the offering. The common shares will be sold at a public offering price of $25.75 per share. The Company has also granted the underwriters an option to purchase up to 600,000 additional shares. The offering is expected to close on or about December 19, 2014, subject to customary closing conditions.
Gilead Sciences Inc. (NASDAQ:GILD)’s shares declined 0.63% to $105.17. The company on Dec. 15 announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, Executive Vice President, Clinical Research and will have responsibility for Gilead’s programs in oncology. Dr. Bishop will also join Gilead’s Executive Committee.
Additionally, the company on Dec. 8 announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig® (idelalisib) in relapsed patients with chronic lymphocytic leukemia (CLL) and two types of indolent non-Hodgkin lymphoma (iNHL).
Celgene Corporation (NASDAQ:CELG)’s shares declined 1.05% to $111.08. The company on Dec. 9 announced that data were presented from a phase 1b/2 study of ISTODAX® (romidepsin) combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with peripheral t-cell lymphoma were presented during the 56th American Society of Hematology annual meeting. In the phase Ib and phase II portions of this study, presented by Jehan Dupuis, M.D. (from the Lymphoma Study Association or LYSA), a total of 37 patients were treated with romidepsin at varying doses plus CHOP. Based on results from phase I (n=18), the recommended dose of romidepsin for the phase II portion was 12 mg/m2 (n= 19).
thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.
Oil Declines Pending U.S Rig Count; Concerns Over High Global Supply
Oil prices declined on Friday, with U.S. crude down 3%, as investors and traders waited anxiously to see if the U.S. oil rig count will fall even more while OPEC members indicated they would do little to cut output. Declining share prices on Wall Street, which have given guidance to oil recently, also pressured crude futures, addition with reduced political turmoil in the Middle East from United States-Russia discussions on Syria. The dollar bounced to contain oil and additional commodities, following Thursday’s decision by the Fed to keep U.S interest rates unchanged pushed the currency to a 21 day low earlier.
This directed attention largely on oil services firm Baker Hughe’s weekly United States oil rigs report set at 1:00p.m EDT. U.S oil drillers have slashed rigs over the last two weeks, a signal that renewed price drops since July possibly be slowing some from returning to the well pad in large way. “With U.S. output shifts still very much under the microscope, today’s oil rig counts could be a key determinant as to how the complex finishes this week,” said Jim Ritterbusch, analyst at Ritterbusch & Associates. “We expect another decline but one downsized from recent double digit decreases,” he stated. U.S crude futures CLcl fell $1.20, or 2.6%, at $45.70 per barrel.
Next, OPEC member Kuwait stated it would take time for the oil markets to correct itself, representing the group would still defend market share regardless of production cuts to boost prices. Additional OPEC sources stated they project oil will increase a maximum $5 a barrel annually to reach $80 by the year 2020. Iran’s deputy oil minister repeated Iran’s plans to get back its oil production share once nuclear-related sanctions are gone against Tehran, enhancing that new oil contracts would be released in coming weeks. Russia was the only main producer to state on Friday it was probably going to cut production at below $40 a barrel.
Illegal Marijuana: Is That Still A Thing?
Marijuana has finally been made legal and will continue to be made legal over the next couple of years throughout the country. However, there is still a need for marijuana to be sold through the black market. Why? Because of taxes.Regulators have made it near impossible for legal markets get out of restriction. Because of this, while cannabis is allowed in certain areas, drug lords and street dealers have been doing exceptionally well.
A main concern is the banking limits put upon cannabis markets. Dealings have been approved by the government, but still are a threat to the industry because no definitive law has been amended to the books. Lawmakers in Washington D.C. recently added a 37 percent excise tax and restricted the number of retail locations. This put the legal market in a state of non competitiveness with the underground trade. Lawmakers are going to have to levy taxes and release oppressing rules if they seek to stop illegal drug trading.
Find out which companies are good marijuana stocks to buy, here.
Marijuana Stocks Are The Highlight Of MarijuanaStocks.com Late Night Analysis
Within the capital markets public companies keep sprouting from, it seems, out of nowhere to try and carve out their own green footprint. Cannabis stocks, as volatile as they may be, continue to captivate investors looking to grab their own piece of a brand new industry, the same way their parents did ten plus years ago with “DotCom.” Dot Bong seems to be the millennials’ turn at finding the next Ebay or Amazon. Think about it, if you could have invested in alcohol just as prohibition was ending, would you (assuming that there was an opportunity to purchase shares of a publicly traded alcohol company)? I will be presumptuous and say “yes”f or you; and that’s exactly what’s happening. Marijuana is the newest “sin” sector in the public markets, joining the likes of big tobacco, Alcohol, and Gaming industry. When the discussion about marijuana stocks comes about, where do you stand? Do you find yourself in the same mindset of at least 7 high net worth investment funds taking the leap into buying cannabis stocks or are you still watching from the sidelines?